摘要
肺癌脑转移作为颅内常见的占位之一，在神经外科越来越受到重视。其生存期短，生存质量差，使患者承担着巨大的生理痛苦和精神压力。手术是治疗肺癌脑转移的主要手段，但受肿瘤占位切除术适用范围的限制，很多病例并不能接受手术治疗。为了应对这一问题，改善患者预后，相继出现了放化疗、靶向治疗、免疫治疗等重要的辅助治疗手段。有充分的临床证据证实这些治疗方案延长了患者的生命，提高了患者生存质量。但是目前临床工作中，没有对肺癌脑转移治疗的统一标准，因此了解各治疗方式的优势利弊，才能充分发挥这些治疗手段的作用，使患者的预后最优化。
Metastatic encephaloma from lung carcinoma is one of the most common intracranial tumors, which is paid to more and more attentions in Neurosurgery. Patients with metastatic neoplasm suffer great physiological and psychological pain for short survival time and survival of poor quality. In terms of treatment, surgery is the major method for metastatic encephaloma of lung cancer. But the subject range of surgery is limited to many factors, therefore many patients can not be treated with surgery. In order to solve the issue of applicability restriction, diversified adjuvant treatment strategies appear successively, such as chemotherapy, targeted therapy, immunotherapy. It has been verified by a number of clinical evidences that these therapies can prolong lifetime and improve living quality of patients. But at the present stage, there is no an uniform standard for the treatment of metastatic encephaloma from lung carcinoma. To give full play the role of each treatment, it is important to understand the advantages and disadvantages. Only in this way, can the patientg interests be optimized.
出处
《国际外科学杂志》
2017年第1期68-72,共5页
International Journal of Surgery
关键词
肺肿瘤
脑转移瘤
分子靶向治疗
Lung neoplasms
Metastatic encephaloma
Moleular targeted therapy
